2017OncotargetOpen access

Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy

Łukasz Koperski, Marta Kotlarek, Michał Świerniak, Monika Kolanowska, Anna Kubiak, Barbara Górnicka, Krystian Jażdżewski, Anna Wójcicka

Open full text 46 citations

Abstract

// Łukasz Koperski 1 , Marta Kotlarek 2 , Michał Świerniak 2, 3 , Monika Kolanowska 2, 3 , Anna Kubiak 2, 3 , Barbara Górnicka 1 , Krystian Jażdżewski 2, 3 and Anna Wójcicka 2, 3 1 Department of Pathology, Medical University of Warsaw, Warsaw, Poland 2 Laboratory of Human Cancer Genetics, Center of New Technologies, CENT, University of Warsaw, Warsaw, Poland 3 Genomic Medicine, Medical University of Warsaw, Warsaw, Poland Correspondence to: Anna Wójcicka, email: anna.wojcicka@uw.edu.pl Keywords: microRNA, adrenocortical carcinoma, cancer diagnostics, next-generation sequencing, NGS Abbreviations: AA, adrenocortical adenoma; ACC, adrenocortical carcinoma; NA, normal adrenal cortex; NGS, next-generation sequencing Received: May 03, 2016 Accepted: March 16, 2017 Published: April 03, 2017 ABSTRACT Background: Adrenocortical carcinoma is a rare finding among common adrenocortical tumors, but it is highly aggressive and requires early detection and treatment. Still, the differential diagnosis between benign and malignant lesions is difficult even for experienced pathologists and there is a significant need for novel diagnostic methods. In this study we aimed to reveal a complete set of microRNAs expressed in the adrenal gland and to identify easily detectable, stable and objective biomarkers of adrenocortical malignancy. Methods: We employed next-generation sequencing to analyze microRNA profiles in a unique set of 51 samples, assigned to either a learning dataset including 7 adrenocortical carcinomas (ACCs), 8 adrenocortical adenomas (AAs) and 8 control samples (NAs), or a validation dataset including 8 ACCs, 10 AAs and 10 NAs. The results were validated in real-time Q-PCR. Results: We detected 411 miRNAs expressed in 1763 length isoforms in the examined samples. Fifteen miRNAs differentiate between malignant (ACC) and non-malignant (AA + NA) tissue in the test set of independent samples. Expression levels of 6 microRNAs, miR-503-5p, miR-483-3p, miR-450a-5p, miR-210, miR-483-5p, miR-421, predict sample status (malignancy/non-malignancy) with at least 95% accuracy in both datasets. The best single-gene malignancy marker, miR-483-3p, has been validated by real-time RT PCR. Conclusions: As a result of the study we propose clinically valid and easily detectable biomarkers of adrenocortical malignancy that may significantly facilitate morphological examination. Since microRNAs can be detected in blood, the study brings tools for development of non-invasive diagnostics of adrenocortical carcinomas.

About this research paper

What this paper is about

// Łukasz Koperski 1 , Marta Kotlarek 2 , Michał Świerniak 2, 3 , Monika Kolanowska 2, 3 , Anna Kubiak 2, 3 , Barbara Górnicka 1 , Krystian Jażdżewski 2, 3 and Anna Wójcicka 2, 3 1 Department of Pathology, Medical University of Warsaw, Warsaw, Poland 2 Laboratory of Human Cancer Genetics, Center of New Technologies, CENT, University of Warsaw, Warsaw, Poland 3 Genomic Medicine, Medical University of Warsaw, Warsaw, Poland Correspondence to: Anna Wójcicka, email: anna.wojcicka@uw.edu.pl Keywords: microRNA, adrenocortical carcinoma, cancer diagnostics, next-generation sequencing, NGS Abbreviations: AA, adrenocortical adenoma; ACC, adrenocortical carcinoma; NA, normal adrenal cortex; NGS, next-generation sequencing Received: May 03, 2016 Accepted: March 16, 2017 Published: April 03, 2017 ABSTRACT Background: Adrenocortical carcinoma is a rare finding among common adrenocortical tumors, but it is highly aggressive and requires early detection and treatment. Still, the differential diagnosis between benign and malignant lesions is difficult even for experienced pathologists and there is a significant need for novel diagnostic methods. In this study we aimed to reveal a complete set of microRNAs expressed in the adrenal gland and to identify easily detectable, stable and objective biomarkers of adrenocortical malignancy. Methods: We employed next-generation sequencing to analyze microRNA profiles in a unique set of 51 samples, assigned to either a learning dataset including 7 adrenocortical carcinomas (ACCs), 8 adrenocortical adenomas (AAs) and 8 control samples (NAs), or a validation dataset including 8 ACCs, 10 AAs and 10 NAs. The results were validated in real-time Q-PCR. Results: We detected 411 miRNAs expressed in 1763 length isoforms in the examined samples. Fifteen miRNAs differentiate between malignant (ACC) and non-malignant (AA + NA) tissue in the test set of independent samples. Expression levels of 6 microRNAs, miR-503-5p, miR-483-3p, miR-450a-5p, miR-210, miR-483-5p, miR-421, predict sample status (malignancy/non-malignancy) with at least 95% accuracy in both datasets. The best single-gene malignancy marker, miR-483-3p, has been validated by real-time RT PCR. Conclusions: As a result of the study we propose clinically valid and easily detectable biomarkers of adrenocortical malignancy that may significantly facilitate morphological examination. Since microRNAs can be detected in blood, the study brings tools for development of non-invasive diagnostics of adrenocortical carcinomas.

Why it matters

OpenAlex reports 46 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

// Łukasz Koperski 1 , Marta Kotlarek 2 , Michał Świerniak 2, 3 , Monika Kolanowska 2, 3 , Anna Kubiak 2, 3 , Barbara Górnicka 1 , Krystian Jażdżewski 2, 3 and Anna Wójcicka 2, 3 1 Department of Pathology, Medical University of Warsaw, Warsaw, Poland 2 Laboratory of Human Cancer Genetics, Center of New Technologies, CENT, University of Warsaw, Warsaw, Poland 3 Genomic Medicine, Medical University of Warsaw, Warsaw, Poland Correspondence to: Anna Wójcicka, email: anna.wojcicka@uw.edu.pl Keywords: microRNA, adrenocortical carcinoma, cancer diagnostics, next-generation sequencing, NGS Abbreviations: AA, adrenocortical adenoma; ACC, adrenocortical carcinoma; NA, normal adrenal cortex; NGS, next-generation sequencing Received: May 03, 2016 Accepted: March 16, 2017 Published: April 03, 2017 ABSTRACT Background: Adrenocortical carcinoma is a rare finding among common adrenocortical tumors, but it is highly aggressive and requires early detection and treatment. Still, the differential diagnosis between benign and malignant lesions is difficult even for experienced pathologists and there is a significant need for novel diagnostic methods. In this study we aimed to reveal a complete set of microRNAs expressed in the adrenal gland and to identify easily detectable, stable and objective biomarkers of adrenocortical malignancy. Methods: We employed next-generation sequencing to analyze microRNA profiles in a unique set of 51 samples, assigned to either a learning dataset including 7 adrenocortical carcinomas (ACCs), 8 adrenocortical adenomas (AAs) and 8 control samples (NAs), or a validation dataset including 8 ACCs, 10 AAs and 10 NAs. The results were validated in real-time Q-PCR. Results: We detected 411 miRNAs expressed in 1763 length isoforms in the examined samples. Fifteen miRNAs differentiate between malignant (ACC) and non-malignant (AA + NA) tissue in the test set of independent samples. Expression levels of 6 microRNAs, miR-503-5p, miR-483-3p, miR-450a-5p, miR-210, miR-483-5p, miR-421, predict sample status (malignancy/non-malignancy) with at least 95% accuracy in both datasets. The best single-gene malignancy marker, miR-483-3p, has been validated by real-time RT PCR. Conclusions: As a result of the study we propose clinically valid and easily detectable biomarkers of adrenocortical malignancy that may significantly facilitate morphological examination. Since microRNAs can be detected in blood, the study brings tools for development of non-invasive diagnostics of adrenocortical carcinomas.

Key concepts: Adrenocortical carcinoma, Adrenocortical adenoma, Malignancy, microRNA, Adrenal cortex, Medicine, Cancer, Adenoma

Related papers

Back to paper searchBrowse research topicsOriginal source
Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy — Research Paper | ScholarLens